Upcoming market catalysts in Q4 2022

High-impact catalysts upcoming in the fourth quarter of 2022 include the US approval decisions on teplizumab for type 1 diabetes, sparsentan for IgA nephropathy (IgAN) and adagrasib for non-small-cell lung cancer (NSCLC).

Competing Interests

The author declares no competing interests.

留言 (0)

沒有登入
gif